Foundayo Australia price starts at A$250 a month as the pill stays off the PBS
Lilly's daily GLP 1 pill Foundayo is on the Australian register with a recommended price of A$250 or A$370 for 30 tablets. It is private prescription only and has no PBAC recommendation for subsidy.
Who feels it
-
Patients
Rethink
A cheaper private option, but the full price is paid out of pocket with no PBS subsidy.
-
Prescribers
Adjust
GPs can write private scripts within days for obesity or type 2 diabetes under the TGA criteria.
-
Pharmacies
Adjust
The recommended price is a guide; each pharmacy sets its own and must explain it to patients.
-
Payers
Worth knowing
No PBS role yet; a listing would need a PBAC recommendation and a price deal.
-
Sellers
Passes by
—
The Foundayo Australia price will start at a recommended A$250 for a month of tablets, Eli Lilly said on Tuesday as its daily weight loss pill joined the Australian Register of Therapeutic Goods. The drug is on private prescription only, it is not on the Pharmaceutical Benefits Scheme, and pharmacies may charge more or less than the recommended price.
What the TGA approval covers
Foundayo is the brand name for orforglipron, a daily GLP 1 pill from Lilly. Unlike semaglutide and tirzepatide it is a small molecule, not a peptide, so it can be absorbed from the gut without the strict fasting rules that come with oral semaglutide. The Therapeutic Goods Administration listing covers two uses, each as an addition to diet and exercise. The first is chronic weight management in adults with obesity, or in overweight adults who also have a weight related condition such as high blood pressure, sleep apnea, prediabetes or heart disease. The second is type 2 diabetes, including for patients who cannot take metformin. The pill comes in six strengths, and Lilly told newsGP that scripts could be written in the coming days.
The trial evidence behind the listing comes from Lilly's Phase 3 programme. newsGP reported that people on the highest strength lost up to 12.4 percent of body weight over 72 weeks, compared with 0.9 percent on placebo, figures that count people who stayed on treatment. The main analysis of the published obesity trial, which counts everyone who started, put the average loss at 11.2 percent against 2.1 percent. Most side effects were mild or moderate stomach and bowel problems. Between about 5 and 10 percent of people in the orforglipron groups stopped treatment because of side effects, against 2.7 percent on placebo. Those numbers matter for cost as well as care, because a patient who stops after a few months has paid for a course that delivered little lasting benefit.
What the Foundayo Australia price means at the counter
Lilly has set a recommended retail price of A$250 for a 30 tablet pack of the lower strengths and A$370 for the higher strengths, according to newsGP. Each pharmacy decides its own final price, so patients may see different figures at different counters. Because the drug is not on the PBS, the patient pays the full amount out of pocket each month for as long as treatment continues. The RACGP says the recommended Foundayo Australia price looks cheaper than the private cost of the weekly injections, which may draw patients who could not afford them. A higher strength, though, costs almost 50 percent more than a lower one.
Because the drug is not on the PBS, the patient pays the full amount out of pocket each month for as long as treatment continues.
RACGP President Dr Michael Wright said the pill looks cheaper than the injectable options but stressed that it is still a private prescription, which creates an equity problem while it stays off the PBS. He also described the drug as "a small molecule medication, not a peptide" and said general practitioners are best placed to weigh it against other options and watch for side effects. The table below sets out what is known about the two oral GLP 1 options now approved in Australia. It shows how much of the pricing and subsidy picture is still missing for the semaglutide tablet, which has not yet reached pharmacies.
| Item | Foundayo tablets | Wegovy tablets |
|---|---|---|
| Medicine | Orforglipron, small molecule | Semaglutide, peptide |
| TGA status | On the register, announced November 17, 2026 | Approved earlier in November 2026 |
| Recommended price | A$250 or A$370 per 30 tablets | Not yet announced |
| PBS listing | No PBAC recommendation | No PBAC recommendation |
| Expected availability | Within days | By the end of 2026 |
Why the PBS gap matters for patients
A cheaper pill changes private costs, not public coverage. The Pharmaceutical Benefits Advisory Committee has not recommended either oral option for listing, and no submission timetable has been made public for Foundayo. Until that changes, access depends on whether a patient can keep paying for a long course. Weight loss drugs tend to work only while they are taken, so a monthly price that looks modest adds up to about A$3,000 or more a year at the recommended prices. People with type 2 diabetes face a separate question, because several other diabetes medicines are subsidised under the PBS while this new pill is not, at least for now.
The approval also arrives in a market that the regulator has already tightened. The TGA ended routine compounding of GLP 1 copies, a change we covered when Australia ended GLP 1 compounding, and it has been chasing unapproved products sold online. A lower priced registered pill may draw some people away from those sources, but the agency has given no forecast. Our report on black market peptides and paid influencers shows how large that trade has grown. Patients considering any GLP 1 medicine should get it on a prescription from a registered prescriber, dispensed by a pharmacy, and should not rely on online offers.
What comes next for oral GLP 1 access
Lilly's tablet has already been sold in the United States, where Lilly has set cash prices for it, as our story on Zepbound and Foundayo prices explains. In Australia the next steps are less certain. Novo Nordisk's Wegovy tablets, approved earlier in November, are expected to be prescribable by the end of the year, and their price has not been announced. That oral semaglutide must be taken on an empty stomach, while Lilly's pill has no such rule. A second oral option should add pressure on price over time, though neither company has signalled cuts. Any PBS listing would need a PBAC recommendation followed by a price deal with the government.
General practitioners are likely to field the first wave of questions. Wright said the field is changing quickly and that doctors need to keep up with new options to advise patients well. Payers, including private insurers and employers, have no direct role while the medicines sit outside the PBS, but a future listing would change who pays and on what terms. Pharmacies will need to explain to patients that the recommended price is a guide and that their own price may differ. For now, the main access barrier is cost: eligible patients can get a prescription within days, but only those who can pay the full private price will start treatment.
Conclusion
The Foundayo Australia price gives patients a cheaper private route to a GLP 1 medicine, but not a subsidised one. Until the PBAC acts, the A$250 to A$370 monthly cost falls entirely on patients, and the Wegovy tablet that follows has no announced price yet.
Source newsGP (RACGP), November 17, 2026, citing Eli Lilly and the TGA
Sources
Spotted an error? Tell us through the contact form; we follow the corrections policy.